Kyowa Kirin Co., Ltd.: Neoplasms trials
The registry lists 14 Neoplasms studies with Kyowa Kirin Co., Ltd. as lead sponsor. 1 are open to participants now and 3 have results posted.
Phase 1 7Phase 2 4Phase 3 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin LymphomaRecruitingNCT07192471Phase 1
- Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid TumorsCompletedNCT02705105Phase 1/2Results posted
- Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal CancerTerminatedNCT00838578Phase 1/2Results posted
- Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer PatientsCompletedNCT00263575Phase 3Results posted
- KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT02867007Phase 1
- Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)CompletedNCT01611142Phase 2
- Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian CancerTerminatedNCT01279291Phase 1
- A Phase 1 Study of ARQ 197 in Patients With Solid TumorsCompletedNCT00609921Phase 1
- Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular OpioidsCompletedNCT00589823Phase 3
- Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular OpioidsCompletedNCT00459277Phase 3
- Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer PainCompletedNCT00458510Phase 3
- A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's LymphomaCompletedNCT00457782Phase 1
- Clinical Study of KW-2246 in Patients With Cancer PainCompletedNCT00355628Phase 2
- Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.CompletedNCT00262678Phase 3